Investigational drug · Phase 2
VAL-083
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Glioma, Glioblastoma, Glioblastoma Multiforme.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 29, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
7
Any phase or sponsor naming "VAL-083"
First trial start
2017
Jan 20, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VAL-083", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glioma
- Glioblastoma
- Glioblastoma Multiforme
- GBM
- Brain Cancer
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "VAL-083" as an intervention, largest first.
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaPivotal-lookingRecruiting
Global Coalition for Adaptive ResearchAcademic, hospital or other
NCT03970447 · 2,250 participants (planned) · Start Jul 30, 2019 · Primary completion Jun 2028
Drug: Temozolomide; Lomustine and 8 more · For: Glioblastoma
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 63 sites in all
Kintara Therapeutics, Inc.Industry
NCT02717962 · 118 participants · Start Jan 20, 2017 · Primary completion Dec 30, 2024
Drug: VAL-083, Dianhydrogalactitol · For: Glioma; Glioblastoma; Glioblastoma Multiforme and 2 more
Sites: Houston, Texas
Kintara Therapeutics, Inc.Industry
NCT01478178 · 55 participants · Start Oct 2011 · Primary completion Dec 2015
Drug: VAL-083 (Dianhydrogalactitol) · For: Glioma; Glioblastoma; Glioblastoma Multiforme and 2 more
Sites: San Francisco, California; Denver, Colorado; Sarasota, Florida · 5 sites in all
Kintara Therapeutics, Inc.Industry
NCT03050736 · 29 participants · Start Dec 17, 2017 · Primary completion Nov 22, 2021
Drug: VAL-083 (Dianhydrogalactitol) · For: Glioma; Glioblastoma; Glioblastoma Multiforme and 2 more
Sites: Guangzhou, China
- VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBMPivotal-lookingTerminated
DelMar Pharmaceuticals, Inc.Industry
NCT03149575 · 2 participants · Start Oct 27, 2017 · Primary completion May 31, 2019
Drug: VAL-083, Dianhydrogalactitol; Physician's Choice of Salvage Therapy - temozolomide and 2 more · For: Glioblastoma Multiforme; Glioblastoma; Glioma and 2 more
Sites: Los Angeles, California; San Francisco, California; Rochester, Minnesota · 5 sites in all
- A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian CancerWithdrawn
DelMar Pharmaceuticals, Inc.Industry
NCT03281681 · 0 participants · Start Mar 2021 · Primary completion Mar 2022
Drug: VAL-083, Dianhydrogalactitol · For: Ovarian Cancer
Sites: Phoenix, Arizona; Detroit, Michigan; Nashville, Tennessee
- Expanded Access to VAL-083No longer available
Kintara Therapeutics, Inc.Industry
NCT03138629
Drug: VAL-083 · For: Cancer
Newest research
PubMed records naming it or its code names, newest first.
- VAL-083 is effective in patients with newly-diagnosed MGMT-unmethylated glioblastoma: report of phase II study.
Guo C, Yang Q, Deng M, et al. · Discov Oncol 2025
- Dual treatment with Val-083 and AZD1775 shows potent anti-tumor activity in diffuse midline glioma models.
Subramaniam B, Roy D, Woldegerima A, et al. · NPJ Precis Oncol 2025
- Neurocytological Advances in the Treatment of Glioblastoma Multiforme.
Fiani B, Covarrubias C, Onyedimma C, et al. · Cureus 2021
- Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma.
Jiménez-Alcázar M, Curiel-García Á, Nogales P, et al. · Mol Cancer Ther 2021
- Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology.
Golebiewska A, Hau AC, Oudin A, et al. · Acta Neuropathol 2020
Also in development for Glioma
- SafusidenibDS-1001b, AB-218Phase 34 trials
Nuvation Bio Inc. · Oligodendroglioma, Glioma, IDH1-mutant Glioma
- APG-157Phase 33 trials
Aveta Biomics, Inc. · Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
- silevertinibBDTX-1535Phase 22 trials
Black Diamond Therapeutics, Inc. · Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM
- HX301Phase 21 trial
Hangzhou Hanx Biopharmaceuticals, Ltd. · Glioma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.